Abstract:Twenty-five to thirty percent of patients with node-negative breast cancer are expected to relapse following surgery, therefore great efforts have been made to identify new prognostic markers that could be useful in defining patients for additional therapy. The expression of MMP-2 and MMP-9 has been associated with high potential of metastasis in several human carcinomas including breast cancer. In the present study we examined the prognostic value of immunoreactive MMP-2/MMP-9 protein in 270 consecutive lymph node negative cases who received radical mastectomy or modified radical mastectomy. Among the patients, 211 cases received adjuvant endocrine therapy and/or adjuvant chemotherapy. Using immunohistochemical assay, we found that 56.7% of the resected tumors were positive for MMP-2 whereas 59.6% of the samples were positive for MMP-9. χ 2 test demonstrated a significant direct association between MMP-2 and MMP-9 ( p < 0.001); positive immunostaining of MMP-2 was significantly related to higher tumor grade ( p < 0.001) and larger tumor size ( p =0.012); positive immunostaining of MMP-9 was significantly related to higher tumor grade ( p =0.002). In univariate analysis, using Cox-proportional hazard model we found MMP-2, MMP-9 and the co-expression of MMPs (MMP2/MMP9) were significantly associated with patients' relapse free survival ( p =0.016, 0.015 and 0.013 respectively) but not overall survival ( p =0.122, 0.320 and 0.091 respectively). Log-rank test also showed that MMP-2, MMP-9 or the co-expression of MMP2/MMP9 was unfavorable prognostic factor for relapse free survival but not overall survival. In subgroup analysis, we found MMPs were more prognostic for patients with no adjuvant treatment than for patients with adjuvant therapy. In multivariate analysis, using Cox-proportional hazard model we found co-expression of MMPs, larger tumor size and higher tumor grade were unfavorable for relapse free survival ( p =0.038, 0.007 and 0.015 for each). We concluded that MMP-2 and MMP-2 are unfavorable prognostic factors in breast cancer patients. They might be potential predictive factor for adjuvant systemic therapy. The co-expression of MMP-2 and MMP-9 has significantly prognostic value in node-negative patients.

Combination of Strong MMP-2 and Weak TIMP-2 Immunostainings Is a Significant Prognostic Factor in Endometrial Carcinoma

Matrix metalloproteinase-1 expression in breast carcinoma: a marker for unfavorable prognosis.

The Expression of Matrirx Metalloproteinase and Tissue Inhibitor of Metallo-proteinase in Endometrial Child Care

Expressions of Matrix Metalloproteinases-2 and Its Tissue Inhibitor-2 and Microvessel Density in Endometrial Carcinoma

Prognostic Value of Matrix Metalloproteinases (MMP-2 and MMP-9) in Patients with Lymph Node-Negative Breast Carcinoma

Prognostic Significance of Matrix Metalloproteinase 7 Immunohistochemical Expression in Colorectal Cancer: a Meta-Analysis.

PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas

Expressions of matrix metalloproteinase-3 and matrix metalloproteinase-10 in endometrial carcinoma

Prognostic Significance of MMP-2 and TIMP-2 Expression in Infiltrating Breast Cancer

Expression and Significance of MMP-2 and TIMP-2 in Human Colorectal Carcinoma and Its Metastasis

Identification of TIMP2 As a Prognostic Biomarker and Its Correlation with Tumor Immune Microenvironment: A Comprehensive Pan-Cancer Analysis

Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma

The expressions and significance of MMP-2 and TIMP-2 in human pancreatic carcinoma

Expressions of Matrix Metalloproteinases in Early-Stage Oral Squamous Cell Carcinoma as Predictive Indicators for Tumor Metastases and Prognosis

Clinical Implications and Prognostic Value of Five Biomarkers in Endometrial Carcinoma

The Relationship Between Expression of Matrix Metalloproteinase -2 in Trophoblastic Tumor and the Patients' Clinical Outcome

Prognostic implications of immunohistochemistry in patients with endometrial cancer

The Prognostic Significance of Co-Expression of Α-Sma and Trichrome in the Tumor Microenvironment of Poorly Differentiated Endometrial Carcinoma

Prognostic Value of Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinase-2 in Bladder Carcinoma.

MMP2 expression is a prognostic marker for primary melanoma patients

The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes